Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on January 27, 2017. The filing reports the entry into a Material Definitive Agreement. Note: The request metadata referenced "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: At-the-market (ATM) Equity Distribution Agreement.
- Counterparty: Maxim Group LLC (Sales Agent).
- Maximum Offering Size: Up to $12,075,338 in shares of common stock.
- Commission Rate: Fixed at 3.5% of the gross sales price.
- Proceeds Usage: Funding research and development for CERC-501 and CERC-611, pursuing partnerships/collaborations, and general working capital.
- Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics. It is a current report regarding a specific agreement.
Material Changes and Terms
The Company entered into a new distribution agreement allowing for the sale of shares from time to time via the Nasdaq Capital Market. Key terms include:
- Flexibility: The Company has no obligation to sell shares and may suspend offers at any time.
- Termination: The offering terminates on the earliest of: (a) January 27, 2018; (b) sale of all shares; or (c) mutual written termination.
- Expenses: The Company will reimburse Maxim for certain expenses and provide indemnification.
Outlook, Risks, and Management Commentary
Management intends to utilize net proceeds to advance specific drug candidates (CERC-501 and CERC-611) and support general operations. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current share price to estimate the potential dilution impact of the $12.08 million offering.
- Review the Company's latest 10-K or 10-Q for actual cash on hand and burn rate to assess the necessity of this capital raise.
- Confirm the status of clinical trials for CERC-501 and CERC-611 to evaluate the strategic use of proceeds.
- Monitor future filings for actual sales volumes under the ATM program.